K. Fager

发表

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor

F. Lee, S. Galbraith, Y. Barrett, 2008, Cancer Chemotherapy and Pharmacology.

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure

Zheng Yang, David Kan, F. Lee, 2006, Clinical Cancer Research.

Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.

J. Tokarski, B. Koplowitz, J. Hunt, 2005, Bioorganic & medicinal chemistry letters.

Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model

F. Lee, R. Kramer, T. Wong, 2005, Clinical Cancer Research.

BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo

F. Lee, C. Fairchild, R. Borzilleri, 2005 .

Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels

F. Luo, S. Castaneda, I. Inigo, 2006, Molecular Cancer Therapeutics.

Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668

F. Lee, N. Donato, M. Talpaz, 2004 .

Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft

F. Lee, R. Kramer, F. Luo, 2005, Cancer Chemotherapy and Pharmacology.

BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.

F. Lee, R. Borzilleri, F. Luo, 2004 .